Advertisement

Organisation › Details
Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY)
Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the developmentof biopharmaceutical drugs, the company is also working on the development of a COVID-19 fusion protein. *
![]() |
Start | 2012-09-01 renamed |
Group | Formycon (Group) | |
Predecessor | Nanohale AG | |
![]() |
Industry | DRUGS, BIOGEN, GENERICS (biosimilars / biogenerics) |
![]() |
Person | Brockmeyer, Carsten (Formycon 201305 CEO) |
Person 2 | Combé, Nicolas (Formycon CFO before Nanohale 201102 CFO) | |
![]() |
Region | Martinsried |
Country | Germany | |
Street | 15 Fraunhoferstr. | |
City | 82152 Martinsried | |
Tel | +49-89-864667-100 | |
Address record changed: 2022-09-17 | ||
Basic data | Employees | C: 51 to 100 (2018-12-31) |
Currency | EUR | |
Annual sales | 43,578,217 (revenue, consolidated (2018) 2018-12-31) | |
Profit | 7,098,615 (2018-12-31) | |
Cash | 7,336,154 (2018-12-31) | |
* Document for »About Section«: Leukocare AG. (3/24/21). "Press Release: Leukocare and Formycon Cooperate in the Development of High-quality Biopharmaceuticals". Martinsried. | ||
Record changed: 2024-12-29 |
Advertisement

More documents for Formycon (Group)
- [1] Formycon AG. (12/9/24). "Press Release: MS Pharma Becomes Partner for the Commercialization of FYB202 / Ustekinumab in the MENA Region". Planegg-Martinsried....
- [2] Formycon AG. (1/29/24). "Press Release: Gedeon Richter Becomes Strategic Investor of Formycon via Equity Investment". Munich & Budapest....
- [3] Formycon AG. (2/7/23). "Press Release: Enno Spillner Appointed Chief Financial Officer (CFO) of Formycon AG". Munich....
- [4] Formycon AG. (8/29/22). "Press Release: European Commission Approves FYB201/Ranivisio (Ranivisio - Ranibizumab), a Biosimilar to Lucentis". Munich, Amsterdam & Zug....
- [5] Formycon AG. (8/3/22). "Press Release: U.S. Food and Drug Administration (FDA) Approved FYB201/Cimerli (ranibizumab-eqrn), the First and Only Biosimilar Interchangeable with Lucentis". Munich, Amsterdam & Zug....
- [6] Leukocare AG. (6/30/22). "Press Release: Leukocare Announces New Management Structure to Support Global Set-up and Accelerate Growth". Martinsried....
- [7] Formycon AG. (5/19/22). "Press Release: Formycon Appoints Dr. Stefan Glombitza as CEO and Sets the Course for the Future by Appointing the Two Experienced Pharmaceutical Managers Nicola Mikulcik and Dr. Andreas Seidl to the Executive Board". Munich....
- [8] Leukocare AG. (3/24/21). "Press Release: Leukocare and Formycon Cooperate in the Development of High-quality Biopharmaceuticals". Martinsried....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top